MICVO's 36% ORR in platinum/PD-1-failed HNSCC heads to a pivotal trial the current cash balance cannot fund

Pyxis Oncology is a clinical-stage company developing MICVO, a targeted cancer drug for head and neck cancer in patients who have already failed platinum chemotherapy and prior immunotherapy, and it is not yet approved.

MICVO, a bispecific antibody targeting patients with recurrent or metastatic head and neck squamous cell carcinoma who have exhausted platinum and checkpoint inhibitor therapy, posted 36% confirmed ORR and 79% twelve-month OS probability in Phase 1 data. The thesis resolves on whether MICVO secures financing sufficient to run the 500-patient Headliner trial, as $34M in cash covers only to Q2 2027, before pivotal initiation. Single-arm Phase 1 data driving a randomized pivotal design means registrational-quality efficacy remains unproven, and Iovance's approved TIL therapy lifileucel addresses the same platinum/checkpoint-failed HNSCC population.